WO1996014333B1 - Peptides for anti-allergy treatment - Google Patents
Peptides for anti-allergy treatmentInfo
- Publication number
- WO1996014333B1 WO1996014333B1 PCT/GB1995/002580 GB9502580W WO9614333B1 WO 1996014333 B1 WO1996014333 B1 WO 1996014333B1 GB 9502580 W GB9502580 W GB 9502580W WO 9614333 B1 WO9614333 B1 WO 9614333B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- xaa
- carrier
- conjugates
- phe
- amino acid
- Prior art date
Links
- 230000003266 anti-allergic Effects 0.000 title claims abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 4
- 125000000539 amino acid group Chemical group 0.000 claims abstract 5
- 239000000969 carrier Substances 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- GKZIWHRNKRBEOH-HOTGVXAUSA-N Phe-Phe Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)C1=CC=CC=C1 GKZIWHRNKRBEOH-HOTGVXAUSA-N 0.000 claims 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 2
- 108010073025 phenylalanylphenylalanine Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 125000002068 L-phenylalanino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001264 neutralization Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920002469 poly(p-dioxane) polymer Polymers 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
Abstract
Peptides of the above-mentioned sequence wherein Xaa is any amino acid residue, but most preferably Val or Ile, and their simple derivatives, including those chain-extended at the N-terminus or C-terminus, are useful in anti-allergy treatment.
Claims
1. Conjugates of peptides of the general formula Phe Phe Xaa Phe (SEQ ID NO: 3) or an N-terminal and/or C-terminal derivative thereof linked to a carrier, wherein Xaa is any amino acid residue and the derivative is a terminally blocked or inactivated peptide or has up to 4 additional amino acids at each terminus.
2. Conjugates of peptides of the general formula Phe Phe Xaa Phe (SEQ ID NO: 3) or an N-terminal and/or C-terminal derivative thereof linked to a carrier, wherein Xaa is any amino acid residue and any one of the Phe residues is replaced by a Trp or Tyr.
3. Conjugates according to claim 1 or 2 wherein Xaa is selected from the group of amino acid residues which comprises Val, lie, Asp, Glu, Lys, Arg and His.
4. Conjugates according to any preceding claim where Xaa is selected from the group of amino acid residues which comprises Val and Ile.
5. Conjugates according to any preceding claim wherein the additional amino acid(s) are either neutral residue (s) or a single N-terminal arginine or lysine residue.
6. Conjugates according to any preceding claim wherein the carrier is a protein or wherein two or more residues of a peptide according to claim 1 or 2 are linked to a branched core.
7. Conjugates according to any preceding claim for use in anti-allergy treatment.
8. Use of conjugates according to any one of claims l to 6 for the manufacture of a formulation for use in anti-allergy treatment.
9. A pharmaceutical composition comprising a conjugate claimed in any one of claims 1 to 6, together with an adjuvant.
10. A method of treating a patient suffering from or susceptible to an allergy which comprises administering to the patient an amount of a conjugate according to any one of claims 1 to 6, effective to combat the allergy.
11. A process for synthesising a conjugate according to any one of claims 1 to 6 which comprises synthetically preparing a peptide by combining amino acids in the sequence shown in SEQ ID NO: 3.
12. A process for synthesising a conjugate according to any one of claims 1 to 6 which comprises covalently binding a carrier to the protein product of the process of claim 11.
13. Conjugates according to any one of claims 1 to 6 wherein the carrier is KLH, tetanus-toxoid or PPD.
14. Conjugates according to any one of claims 1 to 6 wherein the carrier is selected from the group consisting of : 
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU38111/95A AU707483B2 (en) | 1994-11-04 | 1995-11-03 | Peptides for anti-allergy treatment |
| DE69509673T DE69509673T2 (en) | 1994-11-04 | 1995-11-03 | PEPTIDES FOR TREATING ALLERGIES |
| JP8515135A JPH10509700A (en) | 1994-11-04 | 1995-11-03 | Antiallergic therapeutic peptide |
| DK95936020T DK0789710T3 (en) | 1994-11-04 | 1995-11-03 | Peptides for anti-allergic treatment |
| EP95936020A EP0789710B1 (en) | 1994-11-04 | 1995-11-03 | Peptides for anti-allergy treatment |
| US08/817,933 US5945104A (en) | 1994-11-04 | 1995-11-03 | Peptides for anti-allergy treatment |
| GR990401863T GR3030777T3 (en) | 1994-11-04 | 1999-07-14 | Peptides for anti-allergy treatment |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9422294.0 | 1994-11-04 | ||
| GB9422294A GB9422294D0 (en) | 1994-11-04 | 1994-11-04 | Peptides for anti-allergy treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996014333A1 WO1996014333A1 (en) | 1996-05-17 |
| WO1996014333B1 true WO1996014333B1 (en) | 1996-07-11 |
Family
ID=10763914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1995/002580 WO1996014333A1 (en) | 1994-11-04 | 1995-11-03 | Peptides for anti-allergy treatment |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5945104A (en) |
| EP (1) | EP0789710B1 (en) |
| JP (1) | JPH10509700A (en) |
| AT (1) | ATE179989T1 (en) |
| AU (1) | AU707483B2 (en) |
| CA (1) | CA2204256A1 (en) |
| DE (1) | DE69509673T2 (en) |
| DK (1) | DK0789710T3 (en) |
| ES (1) | ES2131339T3 (en) |
| GB (1) | GB9422294D0 (en) |
| GR (1) | GR3030777T3 (en) |
| WO (1) | WO1996014333A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9822763D0 (en) * | 1998-10-20 | 1998-12-16 | Univ Sheffield | Immunoglobin variant |
| US6913749B2 (en) * | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
| US20080118524A1 (en) * | 2006-10-20 | 2008-05-22 | Stefan Persson | Anti-IgE Vaccines |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0000252B1 (en) * | 1977-06-29 | 1982-02-03 | Beecham Group Plc | Peptides, pharmaceutical compositions containing the peptides and a process for the preparation of the peptides |
| US4693993A (en) * | 1985-06-13 | 1987-09-15 | Stewart John M | Bradykinin antagonist peptides |
| EP0288965A2 (en) * | 1987-04-29 | 1988-11-02 | Hoechst Aktiengesellschaft | Peptides with a phospholipase A2 inhibiting activity |
| GB8812214D0 (en) * | 1988-05-24 | 1988-06-29 | Hoffmann La Roche | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
| ES2055785T3 (en) * | 1989-01-17 | 1994-09-01 | Eniricerche Spa | SYNTHETIC PEPTIDES AND THEIR USE AS UNIVERSAL VEHICLES FOR THE PREPARATION OF IMMUNOGENOUS CONJUGATES SUITABLE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES. |
| GB8913737D0 (en) * | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
| IT1237764B (en) * | 1989-11-10 | 1993-06-17 | Eniricerche Spa | SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES. |
| FR2677361A1 (en) * | 1991-06-04 | 1992-12-11 | Adir | NOVEL PEPTIDES AND PSEUDOPEPTIDES, TACHYKININ DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| JP3329868B2 (en) * | 1992-09-30 | 2002-09-30 | 株式会社クラレ | Peptide and adsorbent obtained by immobilizing the peptide on a carrier |
| JPH06113881A (en) * | 1992-10-07 | 1994-04-26 | Snow Brand Milk Prod Co Ltd | Human type monoclonal antipeptide antibody and dna capable of coding the same |
| WO1994018345A1 (en) * | 1993-02-05 | 1994-08-18 | Affymax Technologies N.V. | Receptor-binding antiproliferative peptides |
| GB9320897D0 (en) * | 1993-10-11 | 1993-12-01 | Peptide Therapeutics Ltd | Compounds useful in anti-allergy treatment |
| JP3504963B2 (en) * | 1993-10-22 | 2004-03-08 | 智靖 羅 | DNA fragment encoding amino acid sequence of anti-human high affinity IgE receptor monoclonal antibody |
-
1994
- 1994-11-04 GB GB9422294A patent/GB9422294D0/en active Pending
-
1995
- 1995-11-03 AU AU38111/95A patent/AU707483B2/en not_active Ceased
- 1995-11-03 US US08/817,933 patent/US5945104A/en not_active Expired - Fee Related
- 1995-11-03 CA CA002204256A patent/CA2204256A1/en not_active Abandoned
- 1995-11-03 JP JP8515135A patent/JPH10509700A/en active Pending
- 1995-11-03 DE DE69509673T patent/DE69509673T2/en not_active Expired - Fee Related
- 1995-11-03 AT AT95936020T patent/ATE179989T1/en not_active IP Right Cessation
- 1995-11-03 DK DK95936020T patent/DK0789710T3/en active
- 1995-11-03 EP EP95936020A patent/EP0789710B1/en not_active Expired - Lifetime
- 1995-11-03 ES ES95936020T patent/ES2131339T3/en not_active Expired - Lifetime
- 1995-11-03 WO PCT/GB1995/002580 patent/WO1996014333A1/en active IP Right Grant
-
1999
- 1999-07-14 GR GR990401863T patent/GR3030777T3/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fitton et al. | The amino acid sequence of the delta haemolysin of Staphylococcus aureus | |
| EP0477885B1 (en) | Parathyroid hormone derivatives | |
| AU633913B2 (en) | Novel tnf-inhibit proteins and their preparation | |
| US6080398A (en) | Truncated gro and KC chemokines having enhanced bioactivity | |
| IL184429A (en) | Heterologous fusion proteins comprising a glp-1 compound fused to another polypeptide, pharmaceutical formulations comprising them and use thereof in the preparation of medicaments | |
| AU2126983A (en) | Human pancreatic grf | |
| EP2900255A2 (en) | Insulin analog dimers | |
| JPS6118799A (en) | Effective thymopentin analogue | |
| CA2083360A1 (en) | Tri-arginine insulins | |
| KR101064915B1 (en) | Fusion polypeptide for inhibiting neurotransmitter secretion and method for delivering it | |
| Svendsen et al. | Amino acid sequence homology between human and bovine low molecular weight folate binding protein isolated from milk | |
| Speicher et al. | Structure of human erythrocyte spectrin. I. Isolation of the alpha-I domain and its cyanogen bromide peptides. | |
| REisiNGER et al. | Human inter-α-trypsin inhibitor: localization of the kunitz-type domains in the N-terminal part of the molecule and their release by a trypsin-like proteinase | |
| US5858975A (en) | Oxyntomodulin peptide having cardiotonic activity and insulin release-bromating activity | |
| HU228908B1 (en) | Novel insulin analogs with enhanced zinc binding | |
| BRODIN et al. | Characterization of two substance P antisera | |
| JPH03261800A (en) | Peptide | |
| WO1996014333B1 (en) | Peptides for anti-allergy treatment | |
| HAYASHI et al. | Tetrahymena histone H3. Purification and two variant sequences | |
| SWANN et al. | Characterization of turkey myelin basic protein isolated by a simple procedure | |
| RU99116976A (en) | MYELOPEPTIDES AND THEIR THERAPEUTIC USE | |
| EP1908781A3 (en) | Modulation of immune response and methods based thereon | |
| US5945104A (en) | Peptides for anti-allergy treatment | |
| AU1390795A (en) | Equine arteritis virus peptides, antibodies and their use in a diagnostic test | |
| JPH01287097A (en) | Antitumor protein |